文献速递消化道肿瘤与早癌消化内镜

粪便宏基因组与血清代谢组整合分析揭示肠道菌群相关代谢物在结直肠癌和腺瘤检测中的作用

Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma.
PubMed 文献 · Gut · 2021-08-30

本研究整合粪便宏基因组测序与血清非靶向代谢组学,在结直肠癌和腺瘤患者中识别出885种显著改变的血清代谢物,并构建8种肠道菌群相关血清代谢物(GMSM)组合模型。该模型在建模队列中AUC为0.98(95%CI 0.94-1.00),在验证队列中AUC为0.92(灵敏度83.5%,特异度84.9%),显著优于癌胚抗原(AUC 0.92 vs 0.72),对腺瘤(AUC=0.84)和早期结直肠癌(AUC=0.93)也显示较好诊断准确性。

要点

  • GMSM模型在验证队列中AUC为0.92,灵敏度83.5%,特异度84.9%。
  • GMSM模型诊断性能显著优于癌胚抗原(AUC 0.92 vs 0.72)。
  • GMSM模型对腺瘤和早期结直肠癌也显示较好诊断准确性。

核心结论

  • 结直肠癌患者的肠道菌群重编程与血清代谢组改变相关,GMSM对结直肠癌和腺瘤检测有潜在应用价值。

研究设计与样本

  • 采用液相色谱-质谱联用血清非靶向代谢组学与配对粪便宏基因组测序的整合分析,识别在结直肠癌和腺瘤患者中丰度显著改变的肠道菌群相关代谢物。
  • 通过靶向代谢组学分析验证代谢物区分结直肠癌与结直肠腺瘤的能力,并建立基于肠道菌群相关代谢物的模型在独立验证队列中评估。

主要发现

  • 共有885种血清代谢物在结直肠癌和腺瘤中均显著改变,其中8种肠道菌群相关血清代谢物(GMSM组合)被靶向和非靶向代谢组学重复检测到,并能准确区分结直肠癌和腺瘤与正常样本。
  • 基于GMSM组合的模型预测结直肠癌和结直肠腺瘤在建模队列中AUC为0.98(95%CI 0.94至1.00),在验证队列中AUC为0.92(灵敏度83.5%,特异度84.9%)。
  • GMSM模型在验证队列样本中显著优于临床标志物癌胚抗原(AUC 0.92 vs 0.72),对腺瘤(AUC=0.84)和早期结直肠癌(AUC=0.93)也显示较好诊断准确性。

临床怎么用

  • GMSM模型有潜力作为结直肠癌和腺瘤的无创检测工具,但需进一步外部验证后方可用于临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To profile gut microbiome-associated metabolites in serum and investigate whether these metabolites could distinguish individuals with colorectal cancer (CRC) or adenoma from normal healthy individuals. DESIGN: Integrated analysis of untargeted serum metabolomics by liquid chromatography-mass spectrometry and metagenome sequencing of paired faecal samples was applied to identify gut microbiome-associated metabolites with significantly altered abundance in patients with CRC and adenoma. The ability of these metabolites to discriminate between CRC and colorectal adenoma was tested by targeted metabolomic analysis. A model based on gut microbiome-associated metabolites was established and evaluated in an independent validation cohort. RESULTS: In total, 885 serum metabolites were significantly altered in both CRC and adenoma, including eight gut microbiome-associated serum metabolites (GMSM panel) that were reproducibly detected by both targeted and untargeted metabolomics analysis and accurately discriminated CRC and adenoma from normal samples. A GMSM panel-based model to predict CRC and colorectal adenoma yielded an area under the curve (AUC) of 0.98 (95% CI 0.94 to 1.00) in the modelling cohort and an AUC of 0.92 (83.5% sensitivity, 84.9% specificity) in the validation cohort. The GMSM model was significantly superior to the clinical marker carcinoembryonic antigen among samples within the validation cohort (AUC 0.92 vs 0.72) and also showed promising diagnostic accuracy for adenomas (AUC=0.84) and early-stage CRC (AUC=0.93). CONCLUSION: Gut microbiome reprogramming in patients with CRC is associated with alterations of the serum metabolome, and GMSMs have potential applications for CRC and adenoma detection.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Chen F, Dai X, Zhou CC, et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut. 2021. PMID: 34462336. doi:10.1136/gutjnl-2020-323476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。